Pfizer scraps one weight loss drug in race to develop Ozempic rival
The company's shares fell 3.5% in volatile premarket trading on Monday as Pfizer said it would stop developing its therapy lotiglipron.
Boxes of Ozempic and Mounjaro, semaglutide and tirzepatide injection drugs used for treating type 2 diabetes and made by Novo Nordisk and Lilly, is seen at a Rock Canyon Pharmacy in Provo, Utah, US March 29, 2023.(photo credit: REUTERS/GEORGE FREY)Updated: 
